# Alessandro Russo

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/alessandro-russo/

## Facts

| Field | Value |
| --- | --- |
| Citations | 5,918 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 43 |
| i10-index | 108 |
| Last Known Institution | Humanitas University |
| OpenAlex ID | https://openalex.org/A5008894786 |
| ORCID iD | 0000-0002-3365-1972 |
| Works | 408 |

## Researcher papers

- [Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice](https://scholariq.org/papers/integrated-analysis-of-concomitant-medications-and-oncological-outcomes-from-pd/)
- [RET fusions in solid tumors](https://scholariq.org/papers/ret-fusions-in-solid-tumors/)
- [FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer](https://scholariq.org/papers/folfoxiri-plus-bevacizumab-as-conversion-therapy-for-patients-with-initially/)
- [EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment](https://scholariq.org/papers/egfr-and-her2-exon-20-insertions-in-solid-tumours-from-biology-to-treatment/)
- [A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives](https://scholariq.org/papers/a-decade-of-egfr-inhibition-in-egfr-mutated-non-small-cell-lung-cancer-nsclc-old/)
- [Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study](https://scholariq.org/papers/neutrophil-to-lymphocyte-ratio-nlr-platelet-to-lymphocyte-ratio-plr-and-outcomes/)
- [Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy](https://scholariq.org/papers/differential-influence-of-antibiotic-therapy-and-other-medications-on/)
- [Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)](https://scholariq.org/papers/challenges-and-opportunities-of-cfdna-analysis-implementation-in-clinical/)
- [Liquid Biopsy in Prostate Cancer Management—Current Challenges and Future Perspectives](https://scholariq.org/papers/liquid-biopsy-in-prostate-cancer-management-current-challenges-and-future/)
- [Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going](https://scholariq.org/papers/third-generation-egfr-tkis-in-egfr-mutated-nsclc-where-are-we-now-and-where-are/)
- [Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study](https://scholariq.org/papers/correlation-between-treatments-and-outcomes-of-patients-with-egfr-mutated-non/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)

## Researcher university

- [Humanitas University](https://scholariq.org/institutions/humanitas-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.